Extended follow-up shows DFS benefit for pembrolizumab in MIUC - Urology Times
Adjuvant pembrolizumab (Keytruda) continues to show improved disease-free survival (DFS) vs observation in high-risk muscle-invasive urothelial carcinoma patients after 45 months of follow-up, according to the phase 3 A031501 AMBASSADOR trial. Median DFS was 29.6 months in the pembrolizumab arm vs 14.2 months in the observation arm, with DFS benefits observed regardless of PD-L1 expression and lymph node status.
Related Clinical Trials
Reference News
Adjuvant pembrolizumab (Keytruda) continues to show improved disease-free survival (DFS) vs observation in high-risk muscle-invasive urothelial carcinoma patients after 45 months of follow-up, according to the phase 3 A031501 AMBASSADOR trial. Median DFS was 29.6 months in the pembrolizumab arm vs 14.2 months in the observation arm, with DFS benefits observed regardless of PD-L1 expression and lymph node status.